SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing a sharp sell-off following the announcement that Marvell cancelled purchase orders due to an alleged breach of confidentiality triggered by recent public comments from the company's CFO. While the community remains deeply divided between those calling the stock a fundamental failure and others who view the dip as a tactical buying opportunity, the primary concern is the potential erosion of trust with future hyperscale partners.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing heightened volatility as the community debates its long-term AI strategy, driven by reports that OpenAI may partner with the company to develop custom smartphone processors. Investors remain divided, with some betting on a reversal and AI-driven growth, while others express frustration over recent price fluctuations and persistent short-term bearish sentiment.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as they await topline Phase 3 data from the HAELO trial, which the community sees as a potential validation for their in vivo CRISPR platform. Traders are actively debating the high short interest and the stock's susceptibility to a squeeze, with many weighing the clinical promise of a functional HAE cure against the broader volatility affecting the biotech sector.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is experiencing significant volatility and heavy trading volume as investors debate whether a long-standing insider selling overhang from AE Industrial Partners has finally cleared. The community remains deeply divided, with bulls pointing to strong contract wins and potential tailwinds from the broader space economy, while bears remain skeptical about consistent execution and continued selling pressure.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares is experiencing massive volatility and bullish momentum driven by a strong semiconductor sector rally, fueled by earnings optimism and ongoing AI infrastructure spending. Investors are actively debating whether the current parabolic price action signifies a sustainable super-cycle or a speculative bubble, leading to intense sentiment clashes between bullish 'diamond hands' and traders betting on a sharp mean reversion.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is generating significant investor buzz as it makes its market debut, with the community highlighting its strategic backing from major players like Amazon and Dow to address the surging energy demands of AI data centers. Traders are actively debating the company's valuation and long-term potential compared to other modular nuclear reactor peers, fueled by high initial demand and its positioning as a key player in the clean energy infrastructure space.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

HTCO is seeing intense volatility and social media discussion driven by frequent trading halts and speculation regarding its business model and recent strategic management changes. The community remains deeply divided, with some traders focused on momentum and potential short-squeeze dynamics, while others express significant skepticism about the company's financial structure and long-term outlook.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is trending as investors weigh the significant valuation disconnect between its recent acne trial success and its current market capitalization, while speculation intensifies regarding potential acquisition interest from larger players in the MASH space. Community sentiment remains split between long-term confidence in the drug's multi-indication pipeline and short-term frustration over price volatility and the lack of immediate monotherapy funding for its MASH program.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is drawing significant investor interest as it approaches a high-profile oral presentation of pancreatic cancer data at Digestive Disease Week, which the community views as a critical catalyst for the stock. Traders are actively accumulating shares, citing strong scientific momentum and the company's progress in expanding global clinical trials.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors anticipate upcoming product news at the XRP Las Vegas conference, fueling community enthusiasm about the project's potential in the payments sector. While some traders discuss taking short-term gains, many long-term holders are actively accumulating, viewing the current price as an entry opportunity for a multi-year investment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nike shares fell 2.5% on Wednesday, rising slightly in the after-hours session, ahead of the footwear giant’s Q2 earnings release, with retail sentiment staying bearish.Nike is expected to report earnings on Thursday after the bell. Wall Street is keen to see assurances of how the company is implementing its turnaround strategies under its new CEO.In September, Nike named its former senior executive Elliott Hill as CEO, succeeding John Donahoe amid an attempt to revive sales at the company faced with stiff competition.Hill had been with Nike for 32 years and helped it grow the business to more than $39 billion, according to a Reuters report.Nike is expected to post $0.63 in earnings per share on revenue of $12.11 billion, according to Stocktwits data.The footwear giant beat EPS estimates four times in the past four quarters. But it missed revenue estimates thrice in the same period.Retail sentiment on Stocktwits turned ‘neutral’ from ‘extremely bullish’ a week ago.<figure class="image"><img style="aspect-ratio:1300/314;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_19_at_8_04_02_AM_7b59859109.png" alt="Screenshot 2024-12-19 at 8.04.02 AM.png" width="1300" height="314"><figcaption>NKE sentiment meter and message volumes on Dec 18 as of 9:35 pm ET</figcaption></figure>Many Stocktwits users were speculating a steep fall in its stock price after the earnings. But several were also bullish on its prospects.<stembedurl>https://stocktwits.com/Max9090/message/596944357</stembedurl>Nike's price target was recently lowered by several brokerages.Telsey Advisory lowered the target to $93 from $96 with an Outperform rating, The Fly.com reported. According to the report, the brokerage firm expects a turnaround could happen over the next year, noting that new CEO Elliott Hill's initial strategic view and Q3 guidance should help determine the extent of the company's challenges and the turnaround planMeanwhile, Evercore ISI analyst Michael Binetti also lowered price target to $97 from $105 with an Outperform rating. According to the analyst, Nike is looking to leverage holiday traffic to increase markdowns and increase inventory clearing. The firm lowered its FY25 EPS forecast "significantly" to $2.25 from $2.70 ahead of the company's fiscal Q2 report. The firm also lowers its FY26, FY27 and FY28 EPS forecasts to $2.70, $3.50 and $4.00, respectively.Deutsche Bank analyst Krisztina Katai lowered the price target on Nike to $82 from $92 with a Buy rating and pondering whether he will rebase expectations.A deeper inventory and franchise reset and further investments in the business in the second half of 2025 could put Nike back on a growth path starting in fiscal 2026, according to Deutsche Bank, Fly.com reported.&nbsp; Deutsche Bank foresees “multiple negative earnings revisions in fiscal 2025” as coming or close to an end.Nike stock is down 27.8% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

SAN DIEGO, CALIFORNIA - DECEMBER 13: The Nike corporate logo hangs above their store at Fashion Valley, an upscale shopping mall on December 13, 2024 in San Diego, California. (Photo by Kevin Carter/Getty Images)

Nike Stock Slips Ahead of Q2 Earnings: Retail’s Cautious

Wall Street is keen to see assurances of how the company is implementing its turnaround strategies under its new CEO Elliott Hill.

GBUY
Goldman Sachs ETF Trust - Goldman Sachs Future Consumer Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest GBUY News

GBUYGoldman Sachs ETF Trust - Goldman Sachs Future Consumer Equity ETF